Grace Therapeutics, Inc.
GRCE
$3.21
$0.103.12%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -0.23% | 7.26% | -5.67% | -6.87% | -11.80% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 11.57% | 47.90% | 35.97% | 18.92% | -19.47% |
| Operating Income | -11.57% | -47.90% | -35.97% | -18.92% | 19.47% |
| Income Before Tax | 6.75% | 13.06% | 66.16% | 71.53% | 73.38% |
| Income Tax Expenses | -9.18% | -74.62% | 68.72% | 72.95% | 76.36% |
| Earnings from Continuing Operations | 9.91% | 25.56% | 65.52% | 71.18% | 72.70% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 9.91% | 25.56% | 65.52% | 71.18% | 72.70% |
| EBIT | -11.57% | -47.90% | -35.97% | -18.92% | 19.47% |
| EBITDA | -11.55% | -47.99% | -36.12% | -19.12% | 19.11% |
| EPS Basic | 28.69% | 41.49% | 76.81% | 81.02% | 79.39% |
| Normalized Basic EPS | 25.15% | 22.46% | 12.29% | 36.67% | 36.74% |
| EPS Diluted | 28.69% | 41.49% | 76.81% | 81.02% | 79.39% |
| Normalized Diluted EPS | 25.15% | 22.46% | 12.29% | 36.67% | 36.74% |
| Average Basic Shares Outstanding | 27.21% | 25.76% | 33.68% | 51.87% | 39.24% |
| Average Diluted Shares Outstanding | 27.21% | 25.76% | 33.68% | 51.87% | 39.24% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |